Skip to content

menu

Rothwell, Figg, Ernst & Manbeck, P.C. logo
HomeAboutContact
Rothwell Figg's

Biosimilars Law Bulletin

RegulatoryLegalNews

RFEM’s Biosimilars Inter Partes Review (IPR) Dashboard

RF-Generic-Logo-sm
By Nicole Gifford & Benjamin R. Holt on November 14, 2018
Posted in Legal

RFEM’s Biosimilars IPR Dashboard provides current information on IPR proceedings related to proposed biosimilar products.

Tags: abatacept, adalimumab, Avastin®, bevacizumab, Enbrel®, etanercept, Featured, Herceptin®, Humira®, IPR, Legal, Natalizumab, Neulasta®, News, Orencia®, pegfilgrastim, PTAB, Rituxan®, Rituximab, trastuzumab, Tysabri®, USPTO
Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Related Posts
 BPCIA Litigation Update: Amgen v. Sandoz in the District of New Jersey
June 22, 2023
 Janssen and Amgen Settle Stelara BPCIA Case
May 24, 2023
 Solicitor General Urges the Supreme Court to Reverse the Federal Circuit’s Teva v. GSK Decision
April 18, 2023

Blog Editors

Photo of E. Anthony FiggE. Anthony Figg
Photo of Joseph A. HyndsJoseph A. HyndsMember
Photo of Jennifer P. NockJennifer P. NockMember
Photo of Aydin H. HarstonAydin H. HarstonMember

About this Blog

Authored and edited by attorneys in Rothwell Figg’s Biologics and Biosimilars Group, Rothwell Figg’s Biosimilars Law Bulletin provides updates, articles, and analyses regarding regulatory issues, legal decisions, and other news related to biologics and biosimilars under the Biologics Price Competition and Innovation Act (BPCIA).

Read More....

Stay Connected

RSS LinkedIn Twitter Facebook
Subscribe to this blog

Topics

Archives

Blog Authors Show/Hide

  • D. Lawson Allen
  • Nicole M. DeAbrantes
  • Rachel M. Echols
  • Aydin H. Harston
  • Monica Chin Kitts
  • Paul Macri
  • Malissa Magiera
  • An Nguyen
  • Jennifer P. Nock
  • Gary Prato
  • Andrew J. Storaska
  • Vivian Tian
  • Sheena Wang

Recent Posts

  • BPCIA Litigation Update: Amgen v. Sandoz in the District of New Jersey
  • Janssen and Amgen Settle Stelara BPCIA Case
  • Recent FDA Discussion of Artificial Intelligence for Biosimilar Industry
  • Solicitor General Urges the Supreme Court to Reverse the Federal Circuit’s Teva v. GSK Decision
  • Legislative Efforts to Remove Impediments to Biosimilar Approvals and Marketing

Rothwell Figg Blogs

  • Healthcare Marketing Law
  • Privacy Zone
  • PTAB Law Blog
  • RF EMerge
  • Trademark Opposition Lawyer
Rothwell, Figg, Ernst & Manbeck, P.C.
Washington, DC
901 New York Avenue, NW
Suite 900 East
Washington, DC 20001
202.783.6040
BiosimilarsIPeditors@rothwellfigg.com
Boston
10 Post Office Square
Suite 800 South
Boston, MA 02109
617.312.3101
BiosimilarsIPeditors@rothwellfigg.com
New York
80 South Highland Ave
Ossining, NY 10562
914.941.5668
BiosimilarsIPeditors@rothwellfigg.com
RSS LinkedIn Twitter Facebook
Privacy PolicyDisclaimer

About Our Firm

To learn more about our firm and other practice areas, visit www.rothwellfigg.com.

Copyright © 2023, Rothwell, Figg, Ernst & Manbeck, P.C.. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo